Shanghai Pharmaceuticals Holding's subsidiary company Luosashita Capsules has been approved for production.

17:19 12/06/2026

Shanghai Pharmaceuticals (601607.SH) announced recently that its subsidiary, Shanghai Pharmaceuticals Group Qingdao Guofeng Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" issued by the National Medical Products Administration for Rosusan Capsules, a new type of oral small molecule hypoxia inducible factor prolyl hydroxylase inhibitor. This drug is approved for production and is suitable for treating anemia caused by chronic kidney disease (CKD), including both dialysis and non-dialysis patients.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Holding Group Qingdao Guofeng Pharmaceutical Co., Ltd., has received a Drug Registration Certificate from the National Medical Products Administration for its Roxadustat Capsules. The drug has been approved for production. Roxadustat is a novel oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, used for the treatment of anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.

The largest IPO in US history is born! SpaceX (SPCX.US) lands on Nasdaq with an opening increase of over 11%, speculation of a merger with Tesla, Inc. (TSLA.US) heats up.

US Stock Market Move | Some chip stocks are performing well, with Qualcomm (QCOM.US) rising over 5%.

US Stock Market Move | Most concept stocks in the field of optical communication are rising, with Coherent (COHR.US) increasing by more than 7%.

The largest IPO in US history is born! SpaceX (SPCX.US) lands on Nasdaq with an opening increase of over 11%, speculation of a merger with Tesla, Inc. (TSLA.US) heats up.

US Stock Market Move | Some chip stocks are performing well, with Qualcomm (QCOM.US) rising over 5%.

US Stock Market Move | Most concept stocks in the field of optical communication are rising, with Coherent (COHR.US) increasing by more than 7%.